We believe that the increased availability of medications that have been approved for the treatment of bipolar disorder might be influencing clinicians who are unsure whether or not a patient has bipolar disorder or borderline personality disorder to err on the side of diagnosing the disorder that is responsive to medication.
Такая склонность подкрепляется маркетинговым посланием, которое фармацевтические компании пытаются донести до врачей.